In addition, FLT3 inhibitors have been shown to cause anti-proliferative activity, in leukaemia cell lines with FLT3-ITD, through the downregulation of MCL-1 and BIRC5, the latter via the STAT3/5 pathway [52]. This evidence concerns the gene MCL1 and leukemia.